MentalHealthDaily

Comparison of Brexipiprazole vs. Aripiprazole for Treatment-Resistant Depression (2024 Study)

by GLOOM

Antidepressant-resistant major depressive disorder (AR-MDD) poses significant challenges in psychiatric treatment. Antipsychotics like aripiprazole (ARI) and brexpiprazole (BRE) have emerged as effective adjunct therapies that may be more tolerable than older antipsychotics. Highlights: Both Brexipiprazole and Aripiprazole demonstrated better efficacy than placebo in treating AR-MDD in Japanese patients. Brexipiprazole showed a higher discontinuation rate due …

KNT-127 for Anxiety: Delta Opioid Receptor Agonist via PL-BLA Pathway (2023 Study)

by GLOOM

Recent scientific advancements have illuminated the crucial role of the prelimbic cortex to basolateral amygdala (PL-BLA) pathway in regulating anxiety-like behaviors. Utilizing cutting-edge optogenetic techniques and selective delta-opioid receptor (DOP) agonists, researchers have begun to decode the complex neural circuitry underlying anxiety disorders. Highlights: PL-BLA Pathway Significance: The connection between the prelimbic cortex (PL) and …

Morus Alba (White Mulberry): Medical Uses, Health Effects, Mechanisms (2023 Research)

by GLOOM

Morus alba, a member of the Moraceae family, is not only known for its role in sericulture but also for its therapeutic potential. The plant’s traditional uses are backed by scientific research, indicating its effectiveness in various medical conditions. Highlights: Morus alba is utilized in traditional medicine for its analgesic, antibacterial, antidiabetic, and anti-inflammatory properties. …

Low Dose LSD for Depression Treatment: Preliminary Efficacy (2023 Study)

by GLOOM

Recent research exploring the use of low doses of LSD (Lysergic acid diethylamide) in treating depression marks a significant shift in the psychiatric landscape. This innovative approach seeks to understand and harness the potential therapeutic benefits of psychedelics, which were once stigmatized and largely overlooked in clinical settings. Highlights: Study Design: The research employed a …

Medical Cannabis for Generalized Anxiety Disorders & Sleep Disturbances (2023 Study)

by GLOOM

Recent research has shed light on the potential benefits of cannabis-based medicinal products (CBMPs) in treating Generalized Anxiety Disorder (GAD), especially in patients with sleep disturbances. Recent research explored the effectiveness of CBMPs on GAD, the role of sleep quality in treatment outcomes, and the incidence of adverse events. Highlights: CBMPs Show Promise in Treating …

Psychedelics for Depression: Targeting the 5-HT2A Receptor & Beyond (2023 Study)

by GLOOM

The quest for effective treatments for Major Depressive Disorder (MDD) has taken a revolutionary turn with the exploration of psychedelic compounds. Recent research has evaluated the potential of substances like psilocybin and lisuride, offering new hope for patients unresponsive to traditional antidepressants. Highlights: Traditional Limitations: Standard antidepressants often fail to provide relief for 30% of …

Olibanum Gum Ineffective for Mild-to-Moderate Alzheimers Disease (2023 Study)

by GLOOM

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by cognitive decline, significantly impacting the elderly. A recent clinical trial investigated the memory-improving potential of Olibanum, a traditional herbal remedy, in AD patients. Highlights: Alzheimer’s disease is a leading cause of dementia, characterized by memory loss and cognitive impairment. Olibanum, also known as Frankincense, has a …